OP15L
Anti-c-ErbB2/c-Neu (Ab-3) Mouse mAb (3B5)
lyophilized, clone 3B5, Calbiochem®
Synonym(s):
Anti-HER2, Anti-Neu, Anti-ErbB2, Anti-Erythroblastosis Virus, Anti-Human Epidermal Growth Factor
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
UNSPSC Code:
12352203
NACRES:
NA.43
Recommended Products
biological source
mouse
Quality Level
antibody form
purified antibody
antibody product type
primary antibodies
clone
3B5, monoclonal
form
lyophilized
does not contain
preservative
species reactivity
mouse, human
manufacturer/tradename
Calbiochem®
storage condition
OK to freeze
isotype
IgG1
shipped in
ambient
storage temp.
2-8°C
target post-translational modification
unmodified
Gene Information
human ... ERBB2(2064)
General description
Anti-c-ErbB2/c-Neu (Ab-3), mouse monoclonal, clone 3B5, recognizes the ~185 kDa c-ErbB2/c-Neu protein in HEK293 cells. It is validated for WB, IF, IP, and IHC on frozen and paraffin sections.
Purified mouse monoclonal antibody generated by immunizing BALB/c mice with the specified immunogen and fusing with Sp2/0.Ag14 cells (see application references). Recognizes the ~185 kDa c-ErbB2/c-Neu protein.
Recognizes the ~185 kDa c-ErbB2/c-Neu protein in HEK293 cells.
Immunogen
Human
a synthetic peptide (TAENPEYLGLDVPV) corresponding to amino acids 1242-1255 from the C-terminal domain of human c-ErbB2/c-Neu
Application
Frozen Sections (2.5 g/ml)
Immunoblotting (2.5 g/ml, see application references)
Immunofluorescence (2.5 g/ml)
Immunoprecipitation (1 g per sample, see application references)
Paraffin Sections (2.5 g/ml, pressure cooker pre-treatment required, see application references)
Warning
Toxicity: Standard Handling (A)
Physical form
Lyophilized from 20 mM ammonium bicarbonate Buffer, 100 µg FAF-BSA.
Reconstitution
Reconstitue the lyophilized antibody with sterile PBS, pH 7.4, or sterile 20 mM Tris-saline (20 mM Tris containing 0.15 M NaCl), pH 7.4, to yield a final concentration of 100 µg/ml. Lyophilized antibodies should be reconstituted at 4°C with occasional gentle mixing for at least 2 h. Store at 4°C until reconstituted, then store in aliquots at -20°C or at 4°C with 0.1% azide. Freezing of aliquots is best for long term storage of reconstituted product; repetitive freezing and thawing should be avoided.
Analysis Note
Negative Control
HepG2 cells or normal skin
HepG2 cells or normal skin
Positive Control
SK-BR-3 cells or breast carcinoma tissue
SK-BR-3 cells or breast carcinoma tissue
Other Notes
For paraffin sections, we recommend pre-treating with a pressure cooker, but trypsin and heat will also work well. Including 0.05% saponin during staining of paraffin sections may help reduce background. In one study ductal carcinomas in situ displaying large-cell, comedo growth type, were stained while none of 16 ductal carcinomas in situ of small-cell, papillary, or cribriform growth type were stained by this antibody. Antibody should be titrated for optimal results in individual systems.
Mamcs, J.R., et al. 1994. Ann. Surg.219, 332.
Tetu, B., et al. 1994. Cancer73, 2359.
DiFiore, P.P., et al. 1987. Science237, 178.
Slamon, D.J., et al. 1987. Science235, 177.
Varley, J.M., et al. 1987. Oncogene1, 423.
Bargmann, C.I., et al. 1986. Nature319, 226.
Yamamoto, T., et al. 1986. Nature319, 230.
Blick, M., et al. 1984. Blood64, 1234.
Schwab, M., et al. 1984. Cold Spring Harbor Laboratory2, 215.
Tetu, B., et al. 1994. Cancer73, 2359.
DiFiore, P.P., et al. 1987. Science237, 178.
Slamon, D.J., et al. 1987. Science235, 177.
Varley, J.M., et al. 1987. Oncogene1, 423.
Bargmann, C.I., et al. 1986. Nature319, 226.
Yamamoto, T., et al. 1986. Nature319, 230.
Blick, M., et al. 1984. Blood64, 1234.
Schwab, M., et al. 1984. Cold Spring Harbor Laboratory2, 215.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Not finding the right product?
Try our Product Selector Tool.
Storage Class Code
11 - Combustible Solids
WGK
WGK 1
Regulatory Listings
Regulatory Listings are mainly provided for chemical products. Only limited information can be provided here for non-chemical products. No entry means none of the components are listed. It is the user’s obligation to ensure the safe and legal use of the product.
JAN Code
OP15L-100UG:
OP15L-MG:
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
B Spänkuch et al.
Oncogene, 26(39), 5793-5807 (2007-03-21)
Commonly used drugs for the treatment of breast cancer patients like paclitaxel and Herceptin often show severe side effects or induce resistance in clinical settings. Thus, we analysed a combination of Plk1 (polo-like kinase 1)-specific small interfering RNAs (siRNAs), a
Karin Haim et al.
Neoplasia (New York, N.Y.), 13(3), 230-243 (2011-03-11)
The tumor microenvironment contains multiple cancer-supporting factors, whose joint activities promote malignancy. Here, we show that epidermal growth factor (EGF) and estrogen upregulate in an additive manner the transcription and the secretion of the angiogenic chemokine CXCL8 (interleukin 8 [IL-8])
Soo-Hyun Kim et al.
Disease models & mechanisms, 11(7) (2018-05-23)
Breast cancer brain metastases remain largely incurable. Although several mouse models have been developed to investigate the genes and mechanisms regulating breast cancer brain metastasis, these models often lack clinical relevance since they require the use of immunocompromised mice and/or
Marianne K Kim et al.
BMC cancer, 16, 678-678 (2016-08-26)
shRNA-mediated lethality screening is a useful tool to identify essential targets in cancer biology. Ovarian cancer (OC) is extremely heterogeneous and most cases are advanced stages at diagnosis. OC has a high response rate initially, but becomes resistant to standard
Björn Kruspig et al.
Science translational medicine, 10(446) (2018-06-22)
KRAS is the most frequently mutated driver oncogene in human adenocarcinoma of the lung. There are presently no clinically proven strategies for treatment of KRAS-driven lung cancer. Activating mutations in KRAS are thought to confer independence from upstream signaling; however
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service